A series of 96 patients with severe hypertension has been treated with pentolinium tartrate for an average period of 12 months. Seventeen patients died. Therapy was more effective in arresting changes in the optic fundi and in the heart than in the kidneys. Various combinations of hypotensive agents were tested and it was concluded that in general the combination of pentolinium tartrate, Rauwolfia and hydralazine resulted in the greatest reduction of blood pressure with the least degree of side effects due to ganglionic "blockade." S OON after pentolinium tartrate was synthesized by Libman, Pain and Slack,' pharmacologic studies by Wein and Mason2 indicated that it was a potent ganglionic blocking agent with a prolonged duration of action. Preliminary clinical results were reported by Campbell and Maxwell,3 Smirk4 and from this clinic.5 These reports indicated that pentolinium tartrate was an orally effective, potent, antihypertensive drug that appeared to be useful in the treatment of patients with more severe, fixed types of hypertension. In the present report, the long-term experience with pentolinium tartrate both alone and in combination with certain other hypotensive agents is presented.
S OON after pentolinium tartrate was synthesized by Libman, Pain and Slack,' pharmacologic studies by Wein and Mason2 indicated that it was a potent ganglionic blocking agent with a prolonged duration of action. Preliminary clinical results were reported by Campbell and Maxwell,3 Smirk4 and from this clinic.5 These reports indicated that pentolinium tartrate was an orally effective, potent, antihypertensive drug that appeared to be useful in the treatment of patients with more severe, fixed types of hypertension. In the present report, the long-term experience with pentolinium tartrate both alone and in combination with certain other hypotensive agents is presented.
MATERIALS AND METHODS
The treatment group consisted of 96 patients selected because of severe, sustained hypertension (table 1) . Their ages ranged from 27 to 65 years, with an average age of 47 years. All except 15 of these patients were hospitalized prior to or during the initiation of treatment with pentolinium. Prior to therapy, 56 per cent exhibited grade III or more changes in the optic fundi and 39 per cent had some degree of nitrogen retention.
Electrocardiograms were taken of 83 patients and 66 exhibited the pattern of left ventricular hypertrophy. Frank congestive heart failure was diagnosed in 13 of the patients, although lesser degrees of cardiac decompensation as manifested by exertional dyspnea were common. Cardiac enlargement was present in 58 of 76 patients who had roentgenograms taken prior to treatment.
The method of adjusting dosages of pentolinium tartrate has been described in previous communications.6-8 The duration of treatment ranged from 3 to 27 months, with a mean of 12 months. Seven were treated for 24 months or longer, 44 were treated from 12 to 24 months, 26 from 6 to 12 months, and 18 from 3 to 6 months. In the majority of the cases, various other hypotensive agents were added to pentolinium tartrate for periods of time as are described below.
RESULTS

Over-all Results of Treatment Mortality
There were 17 deaths in the entire series. Of these, 10 exhibited grade IV fundi; 4, grade III; and 3, grade II fundi prior to therapy. The survival from beginning of treatment to death in this group averaged 11 months, and in the figure 3 . Side effects due to the addition of Rauwolfia were nasal stuffiness in 18 per cent, severe mental depression in 6 per cent, weight gain in 21 per cent, increase in appetite in 27 per cent, nightmares in 2 patients and diarrhea in 2 cases. In 43 patients it was possible to determine the dosage requirement of pentolinium after, as compared to before, the addition of Rauwolfia (table 6). The average daily dosage of pentolinium when used alone was 550 mg., which produced an average blood pressure fall of 18 per cent in the supine position and 22 per cent in the erect position. After addition of Rauwolfia, the average daily requirement of pentolinium was 422 mg. and the mean reduction of blood pressure was 25 per cent in the supine and 29 per cent in the erect position.
The above data represent over-all averages. In not all of the patients was it possible to reduce the dosage. In 23 or 54 per cent of the 43 patients, the dosage of pentolinium could be decreased, in 16 it remained the same and in 4 it was increased. Twenty-four patients exhibited an additional reduction of 5 Detelopment of "Tolerance" The development of "tolerance" was estimated by comparing the dosage requirement and blood pressure reduction at, the initiation of treatment with that required at the end of the period of this study. The In the patients with cardiomegaly diilninution of cardiac size was observed in approxiimately owe half of the cases. Since the majority of these cases had the usual therapy for congestive heart failure prior to being placed on pentoliniuim tartrate, the improvement appeared to result from the anitihypertensive therapy per se. In fact, in many of these patients the need for salt, restriction or diuretics was reduced or even abolished. In contrast to these evidences of improvement in cardiac status only 12 per cent of patients showed partial or complete reversal of the electrocardiographic pattern of left, ventrictular hypertrophy.
The extent of improvement in the kidneys was less impressive than in the futndi and the heart. In the patients with nitrogen retemition, as many showed increasing uremia as showed clfearing, and five patients developed elevations of blood urea nitrogen or nonprotein nitrogen from normal to abnormal while under treatmnent. The degree of albuminuria in general tended to lessen under therapy. On the other hand the ability of the patients to excrete phenolsulfonphthaleini dye decreased more often than it improved.
It seems possible that the decrease in albuminuria and improvement in nitrogen retention seen in some of the cases might be expected in part, on the basis of improvement in latent or overt, cardiac decompensation. The same might be said for the decrease in nocturia that was frequently noted. The appearanice or worsening of nitrogen retention in other patients while under therapy and the frequent observation of reduced ability to excrete phenolsulfonphthaleiin dye may be accounted for on the basis of two factors: (1) effect of ganiglionic 1locking agents on renal hemodynamnics9 and (2) further progress of the renal lesions despite antihypertensive therapy. The fact that the majority of the deaths ill this FREtS AND WILSON8 sseries were due to renal failure tends to support this thesis. It would appear, therefore, that treatment with pentolinium tartrate is least effective against the renal complications of severe hypertension. If nephrosclerosis results from sustained hypertension these observationis provide an argument for beginning treatment earlier, before the renal arterioles have become irreparably sclerosed.
(1o1firming our previous experience'0 and those of others"' 12 the addition of reserpine not only produces a further reduction of blood pressure in many patients but also may permit reduction of the dosage of pentolinium anld, hence, lessen the incidence of disabling side effects produced by ganglionic "blockade." This combination while effective and generally better tolerated by the patient must be institiuted with an awareness that serious mental (lepression can occur in patients treated for long periods with Rauwolfia preparations. '3 The additive hypotensive effect of hydralazine alone was studied in only a small number of patients and the dosages used were smaller than those employed by Perry and Schroeder in a similar study. 4 Nevertheless, the present results confirm their observation that the additioni of hydralazine produced a further lowering of blood pressure. It is interesting that in ouir cases, where the dosages of hydralazine awere small, the development of the syndrome resembling disseminated lupus erythematosus did not occur; whereas it was not an infrequent eomnplicationi in Perry and Schroeder's series. (h)i the basis of the various observations on small doses of hydralazine and of Raxiwolfia we have concluded that therapy combining all 3 agents produces the greatest reduction of blood pressure and the smallest dosage requirement of the blocking agent. We believe, however, that each drug be added separately inl order to judge its effects in the particular case.
It is interesting that all of the "toxic" reactioins to pentolinium tartrate seemed to be due to the acute effects of ganglioniic "blo(kade." nlikie hexamethonium'5' 16 no cases of chronic interstitial pneumonitis occurred in this series, nor to our knowledge have there been any reports of this complication in the literature on peitolinium tartrate.
The proof of the effectiveness of any form of treatment in hypertension is its ability to prevent morbidity and mortality. The duration of treatment in this series still is too short to draft any conclusions in regard to mortality.
IIi regard to mnorbidity, however, it is important to note that the majority of the patients who had lost their jobs because of severe hypertension were able to return to some sort of gainful occupation. This was also the case ill many of the patients who eventually died but who were able to work until shortly before exitus. The clearing of symptoms of cardiac decompensation or hypertensive encephalopathy produced considerable subjective improvement, in these severe cases. In addition, due to the postural hypotension produced by pentolinium tartrate, the control of blood pressure was as good or better when the patient Adas tup and active thaii when he was inactive. headache, dizziness and those relating to cardiac decompensation often were relieved; whereas those due to vascular sclerosis, such as angina or residuals of old cerebrovascular accidents, usually did not improve or were made worse.
3. Improvement in the optic fundi was observed in more than 80 per cent of the patients with grade III and grade IV changes and in slightly less than half of the patients with grade II changes.
4. Decrease in cardiac size frequently was observed. Improvement in the electrocardiographic pattern of left ventricular hypertrophy also occurred but less frequently than the former.
5. The degree of albuminuria usually tended to lessen during treatment. Approximately half of the patients with nitrogen retention showed clearing, whereas the other half developed increased retention. The ability of the patients to excrete phenolsulfonphthalein decreased more often than it increased following treatment. The reasons for these apparent discrepancies are discussed and it is concluded that treatment was more effective in arresting or reversing changes in the optic fundi and in the heart than in the kidneys.
6. Data are presented to demonstrate the additive effects of Rauwolfia or hydralazine, or both, to the regimen. Combining all three agents generally resulted in the greatest reduction of blood pressure with the least degree of symptoms resulting from ganglionic "blockade."
7. In view of the severity of the hypertension in the present series, it is concluded that this method of treatment is beneficial. 
